论文部分内容阅读
作为治疗肺癌主要手段之一药物化疗,因多重耐药性(MDR)的困扰,疗效受到制约。对MDR产生机制的研究最多的是:MDR基因及其编码的P-170蛋白,谷胱甘肽硫转移酶(GST)和拓扑异构酶Ⅱ(TOPOⅡ)。MDR基因编码的P-170蛋白具有膜转运功能,可将药物排出细胞,GST通过其细胞内解毒作用发挥其抗药功能,TOPOⅡ因其活性降低使一些以其为靶酶的抗肿瘤药物失去效应。从已获得的研究结果来看,肺癌MDR表型产生可能存在多种机制。
As one of the main means for the treatment of lung cancer, chemotherapy has been curtailed by multiple drug resistance (MDR). MDR genes and their encoded P-170 proteins, glutathione S-transferase (GST) and topoisomerase II (TOPOII) are the most studied for the mechanism of MDR production. The PDR protein encoded by the MDR gene has a membrane transport function and can excrete the drug out of the cell. GST exerts its anti-drug function through its intracellular detoxification, and TOPOII loses its effect as an antitumor drug targeting it because of its reduced activity. . From the results obtained, there are many possible mechanisms for the development of MDR phenotypes in lung cancer.